

GOV. MSG. NO. 1361

EXECUTIVE CHAMBERS

DAVID Y. IGE GOVERNOR

July 6, 2021

The Honorable Ronald D. Kouchi, President and Members of the Senate Thirty First State Legislature State Capitol, Room 409 Honolulu, Hawai'i 96813 The Honorable Scott K. Saiki, Speaker and Members of the House of Representatives Thirty First State Legislature State Capitol, Room 431 Honolulu, Hawai'i 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

This is to inform you that on July 6, 2021, the following bill was signed into law:

HB1032 HD1

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT ACT 233 (21)

Sincerely,

fand V.

DAVID Y. IGE Governor, State of Hawai'i

Approved by the Governor

ORIGINAL

JUL\_\_\_\_\_

JUL 0 6 2021

HOUSE OF REPRESENTATIVES THIRTY-FIRST LEGISLATURE, 2021 STATE OF HAWAII

#### ACT 2 3 3 H.B. NO. <sup>1032</sup><sub>H.D.1</sub>

#### A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.


#### BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECTION 1. Section 329-14, Hawaii Revised Statutes, is
2	amended as follows:
3	1. By amending subsection (b) to read:
4	"(b) Any of the following opiates, including their
5	isomers, esters, ethers, salts, and salts of isomers, esters,
6	and ethers, unless specifically excepted, whenever the existence
7	of these isomers, esters, ethers, and salts is possible within
8	the specific chemical designation:
9	(1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-
10	phenethyl)-4-piperidinyl]-N-phenylacetamide);
11	(2) Acetylmethadol;
12	<pre>(3) Allylprodine;</pre>
13	(4) Alphacetylmethadol (except levo-alphacetylmethadol,
14	levomethadyl acetate, or LAAM);
15	(5) Alphameprodine;
16	(6) Alphamethadol;

2021-2263 HB1032 HD1 HMSO

### H.B. NO. <sup>1032</sup> H.D. 1

1	(7)	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-
2		phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-
3		<pre>2-phenylethyl)-4-(N-propanilido) piperidine);</pre>
4	(8)	Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
5		thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
6	(9)	Benzethidine;
7	(10)	Betacetylmethadol;
8	(11)	Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
9		<pre>piperidinyl]-N-phenylpropanamide);</pre>
10	(12)	Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-
11		phenethyl)-3-methyl-4-piperidinyl]-N-
12		<pre>phenylpropanamide);</pre>
13	(13)	Betameprodine;
14	(14)	Betamethadol;
15	(15)	Betaprodine;
16	(16)	Clonitazene;
17	(17)	Dextromoramide;
18	(18)	Diampromide;
19	(19)	Diethylthiambutene;
20	(20)	Difenoxin;
21	(21)	Dimenoxadol;



1	(22)	Dimepheptanol;
2	(23)	Dimethylthiambutene;
3	(24)	Dioxaphetyl butyrate;
4	(25)	Dipipanone;
5	(26)	Ethylmethylthiambutene;
6	(27)	Etonitazene;
7	(28)	Etoxeridine;
8	(29)	Furethidine;
9	(30)	Hydroxypethidine;
10	(31)	Ketobemidone;
11	(32)	Levomoramide;
12	(33)	Levophenacylmorphan;
13	(34)	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
14		<pre>piperidyl]-N-phenylpropanamide);</pre>
15	(35)	3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-
16		<pre>4-piperidinyl]-N-phenylpropanamide);</pre>
17	(36)	Morpheridine;
18	(37)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
19	(38)	Noracymethadol;
20	(39)	Norlevorphanol;
21	(40)	Normethadone;

2021-2263 HB1032 HD1 HMSO

Page 3

#### H.B. NO. <sup>1032</sup><sub>H.D. 1</sub>

1	(41)	Norpipanone;
2	(42)	Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-
3		phenethyl)-4-piperidinyl] propanamide;
4	(43)	PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine;
5	(44)	Phenadoxone;
6	(45)	Phenampromide;
7	(46)	Phenomorphan;
8	(47)	Phenoperidine;
9	(48)	Piritramide;
10	(49)	Proheptazine;
11	(50)	Properidine;
12	(51)	Propiram;
13	(52)	Racemoramide;
14	(53)	Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
15		<pre>piperidinyl]-propanamide);</pre>
16	(54)	Tilidine;
17	(55)	Trimeperidine;
18	(56)	N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
19		(benzylfentanyl), its optical isomers, salts, and
20		salts of isomers;

2021-2263 HB1032 HD1 HMSO

H.B. NO. <sup>1032</sup> H.D. 1

1	(57)	N-[1-(2-thienyl)methyl-4-piperidyl]-N-
2		phenylpropanamide (thenylfentanyl), its optical
3		isomers, salts, and salts of isomers;
4	(58)	N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,
5		(acetyl fentanyl), its optical, positional, and
6		geometric isomers, salts, and salts of isomers;
7	(59)	AH-7921 (3,4-dichloro-N-[(1-dimethylamino)
8		cyclohexylmethyl]benzamide), its isomers, esters,
9		ethers, salts, and salts of isomers, esters, and
10		ethers;
11	(60)	N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its
12		isomers, esters, ethers, salts, and salts of isomers,
13		esters, and ethers (Other names: Butyryl fentanyl);
14	(61)	N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-
15		yl]-N-phenylpropionamide, its isomers, esters, ethers,
16		salts, and salts of isomers, esters, and ethers (Other
17		<pre>names: beta-hydroxythiofentanyl);</pre>
18	(62)	N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-
19		carboxamide, its isomers, esters, ethers, salts, and
20		salts of isomers, esters, and ethers (Other names:
21		Furanyl fentanyl);

2021-2263 HB1032 HD1 HMSO

### H.B. NO. <sup>1032</sup>

1	(63)	3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
2		methylbenzamide, its isomers, esters, ethers, salts,
3		and salts of isomers, esters, and ethers (Other names:
4		U-47700);
5	(64)	4-fluoroisobutyryl fentanyl or para-fluoroisobutyryl
6		[ <del>fenrany]</del> ] <u>fentanyl</u> [N-(4-fluorophenyl)-N-(1-
7		<pre>phenethylpiperidin-4-yl)isobutyramide];</pre>
8	(65)	Acryl fentanyl or acryloylfentanyl [N-(1-
9		phenethylpiperidin-4-yl)-N-phenylacrylamide]; [and]
10	(66)	Ocfentanil [ <del>[N-(2-fluorophenyl)-2-methoxy-N-(1-</del>
11		<pre>phenethylpiprtidin-4-yl)acetamide].] [N-(2-</pre>
12		fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-
13		<pre>yl)acetamide];</pre>
		A
14	(67)	
14 15	(67)	
	<u>(67)</u> (68)	Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
15		Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylcyclopropanecarboxamide;
15 16		Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylcyclopropanecarboxamide; Methoxyacetyl fentanyl (2-methoxy-N-(1- phenethylpiperidin-4-yl)-N-phenylacetamide);
15 16 17	(68)	Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylcyclopropanecarboxamide; Methoxyacetyl fentanyl (2-methoxy-N-(1- phenethylpiperidin-4-yl)-N-phenylacetamide);

2021-2263 HB1032 HD1 HMS0

1	(70) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
2	phenethylpiperidin-4-yl)butyramide)."
3	2. By amending subsection (e) to read:
4	"(e) Depressants. Unless specifically excepted, the
5	schedule shall include any material, compound, mixture, or
6	preparation which contains any quantity of the substance:
7	(1) Mecloqualone; [ <del>or</del> ]
8	(2) Methaqualone [+];
9	(3) Etizolam (including its optical, positional, and
10	geometric isomers, salts, and salts of isomers, where
11	possible); or
12	(4) Flualprazolam (including its optical, positional, and
13	geometric isomers, salts, and salts of isomers, where
14	possible)."
15	3. By amending subsection (g) to read:
16	"(g) Any of the following cannabinoids, their salts,
17	isomers, and salts of isomers, unless specifically excepted,
18	whenever the existence of these salts, isomers, and salts of
19	isomers is possible within the specific chemical designation:
20	(1) Tetrahydrocannabinols; meaning tetrahydrocannabinols
21	naturally contained in a plant of the genus Cannabis

#### 2021-2263 HB1032 HD1 HMS0

#### H.B. NO. <sup>1032</sup> H.D. 1

(cannabis plant), as well as synthetic equivalents of 1 the substances contained in the plant, or in the 2 resinous extractives of Cannabis, sp. or synthetic 3 4 substances, derivatives, and their isomers with similar chemical structure and pharmacological 5 activity to those substances contained in the plant, 6 such as the following: Delta 1 cis or trans 7 8 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans tetrahydrocannabinol, and their optical 9 10 isomers; and Delta 3,4 cis or trans-11 tetrahydrocannabinol, and its optical isomers (since nomenclature of these substances is not 12 13 internationally standardized, compounds of these structures, regardless of numerical designation of 14 atomic positions, are covered); 15 (2) Naphthoylindoles; meaning any compound containing a 3-16 (1-naphthoyl) indole structure with substitution at the 17 18 nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 19 20 1-(N-methyl-2-piperidinyl)methyl or 2-(4morpholinyl)ethyl group, whether or not further 21

2021-2263 HB1032 HD1 HMS0

Page 8

1 substituted in the indole ring to any extent and 2 whether or not substituted in the naphthyl ring to any 3 extent; Naphthylmethylindoles; meaning any compound containing 4 (3) a 1H-indol-3-yl-(1-naphthyl) methane structure with 5 6 substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 7 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 8 2-(4-morpholinyl) ethyl group whether or not further 9 10 substituted in the indole ring to any extent and 11 whether or not substituted in the naphthyl ring to any 12 extent; 13 (4) Naphthoylpyrroles; meaning any compound containing a 14 3-(1-naphthoyl)pyrrole structure with substitution at 15 the nitrogen atom of the pyrrole ring by a alkyl, 16 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) 17 18 ethyl group whether or not further substituted in the 19 pyrrole ring to any extent, whether or not substituted 20 in the naphthyl ring to any extent;



#### H.B. NO. <sup>1032</sup> H.D. 1


1 (5) Naphthylmethylindenes; meaning any compound containing 2 a naphthylideneindene structure with substitution at the 3-position of the indene ring by a alkyl, 3 4 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 5 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the 6 7 indene ring to any extent, whether or not substituted 8 in the naphthyl ring to any extent; 9 (6) Phenylacetylindoles; meaning any compound containing a 10 3-phenylacetylindole structure with substitution at 11 the nitrogen atom of the indole ring by a alkyl, 12 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 13 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) 14 ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted 15 16 in the phenyl ring to any extent; 17 (7) Cyclohexylphenols; meaning any compound containing a 18 2-(3-hydroxycyclohexyl) phenol structure with 19 substitution at the 5-position of the phenolic ring by 20 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 21 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or

2021-2263 HB1032 HD1 HMSO

1		2-(4-morpholinyl) ethyl group whether or not
2		substituted in the cyclohexyl ring to any extent;
3	(8)	Benzoylindoles; meaning any compound containing a 3-
4		(benzoyl) indole structure with substitution at the
5		nitrogen atom of the indole ring by a alkyl,
6		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
7		1-(N-methyl-2-piperidinyl) methyl, or 2-(4-
8		morpholinyl) ethyl group whether or not further
9		substituted in the indole ring to any extent and
10		whether or not substituted in the phenyl ring to any
11		extent;
12	(9)	[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
13		pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-
14		naphthalenylmethanone (another trade name is WIN
15		55,212-2);
16	(10)	(6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-
17		methyloctan-2-yl)-6a,7,10,10a-
18		tetrahydrobenzo[c]chromen-1-ol (Other trade names are:
19		HU-210/HU-211);
20	(11)	Tetramethylcyclopropanoylindoles; meaning any compound
21		containing a 3-tetramethylcyclopropanoylindole

2021-2263 HB1032 HD1 HMSO 

1		structure with substitution at the nitrogen atom of
2		the indole ring by an alkyl, haloalkyl, cyanoalkyl,
3		alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
4		<pre>methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,</pre>
5		1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
6		morpholinyl)methyl, or tetrahydropyranylmethyl group,
7		whether or not further substituted in the indole ring
8		to any extent and whether or not substituted in the
9		tetramethylcyclopropyl ring to any extent;
10	(12)	N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
11		its optical, positional, and geometric isomers, salts,
12		and salts of isomers (Other names: APINACA, AKB48);
13	(13)	Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
14		optical, positional, and geometric isomers, salts, and
15		salts of isomers (Other names: PB-22; QUPIC);
16	(14)	Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
17		carboxylate, its optical, positional, and geometric
18		isomers, salts, and salts of isomers (Other names: 5-
19		fluoro-PB-22; 5F-PB-22);
20	(15)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
21		fluorobenzyl)-1H-indazole-3-carboxamide, its optical,



1		positional, and geometric isomers, salts, and salts of
2		isomers (Other names: AB-FUBINACA);
3	(16)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
4		indazole-3-carboxamide, its optical, positional, and
5		geometric isomers, salts, and salts of isomers (Other
6		names: ADB-PINACA);
7	(17)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
8		(cyclohexylmethyl)-1H-indazole-3-carboxamide, its
9		optical, positional, and geometric isomers, salts, and
10		salts of isomers (Other names: AB-CHMINACA);
11	(18)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
12		indazole-3-carboxamide, and geometric isomers, salts,
13		and salts of isomers (Other names: AB-PINACA);
14	(19)	<pre>[1-(5-fluoropentyl)-1H-indazol-3-yl}(naphthalen-1-</pre>
15		yl)methanone, and geometric isomers, salts, and salts
16		of isomers (Other names: THJ-2201);
17	(20)	Methyl [ <del>{1-(4-fluorobenzyl}-1-H-indazole-3-carbonyl)-</del>
18		L-valinate,] (1-(4-fluorobenzyl)-1H-indazole-3-
19		carbonyl)-L-valinate, and geometric isomers, salts,
20		and salts of isomers (Other names: FUB-AMB[ <del>);</del> ], <u>Methyl</u>

2021-2263 HB1032 HD1 HMS0

H.B. NO. <sup>1032</sup><sub>H.D. 1</sub>

.

1		2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-
2		<pre>methylbutanoate, MMB-FUBINACA, AMB-FUBINACA);</pre>
3	(21)	(S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
4		carboxamido)-3-methylbutanoate, and geometric isomers,
5		salts, and salts of isomers (Other names: 5-fluoro-
6		AMB, 5-fluoro-AMP);
7	(22)	N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
8		indazole-3-carboxamide, and geometric isomers, salts,
9		and salts of isomers (Other names: AKB48 N-(5-
10		fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
11		analog, 5F-APINACA);
12	(23)	N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
13		geometric isomers, salts, and salts of isomers (Other
14		<pre>names: STS-135, 5F-APICA; 5-fluoro-APICA);</pre>
15	(24)	Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
16		carboxylate, and geometric isomers, salts, and salts
17		of isomers (Other names: NM2201);
18	(25)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
19		(cyclohexylmethyl)-1H-indazole-3-carboxamide, and
20		geometric isomers, salts, and salts of isomers (Other
21		names: MAB-CHMINACA and ADB-CHMINACA);

. 2021-2263 HB1032 HD1 HMSO

# H.B. NO. <sup>1032</sup><sub>H.D. 1</sub>

1	(26)	Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-
2		carboxamido]-3,3-dimethylbutanoate (Other names: 5F-
3		ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical,
4		positional, and geometric isomers, salts, and salts of
5		isomers; and
6	(27)	1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-
7		carboxamide (CUMYL-4CN-BINACA), its optical,
8		positional, and geometric isomers, salts, and salts of
9		isomers; also known as SGT-78, 4-CN-CUMYL-BINACA;
10		CUMYL-CB-PINACA; CUMYL-CYBINACA; 4-cyano CUMYL-
11		BUTINACA."
12	SECT	ION 2. Section 329-16, Hawaii Revised Statutes, is
13	amended b	y amending subsection (f) to read as follows:
14	"(f)	Immediate precursor. Unless listed in another
15	schedule,	any material, compound, mixture, or preparation which
16	contains	any quantity of the following substances:
17	(1)	Immediate precursor to amphetamine and
18		methamphetamine:
19		(A) Phenylacetone, phenyl-2-propanone(P2P), benzyl
20		methyl ketone, methyl benzyl ketone;
21	(2)	Immediate precursors to phencyclidine (PCP):

2021-2263 HB1032 HD1 HMSO

1	(A) 1-phenylcyclohexylamine; [and] or		
2	(B) 1-piperidinocyclohexanecarbonitrile(PCC); or		
3	(3) Immediate precursor to Fentanyl:		
4	(A) 4-anilino-N-phenethyl-4-piperidine (ANPP)[+]; or		
5	(B) N-phenyl-N-(piperidin-4-yl)propionamide		
6	(norfentanyl)."		
7	SECTION 3. Section 329-20, Hawaii Revised Statutes, is		
8	amended as follows:		
9	1. By amending subsection (b) to read:		
10	"(b) Depressants. Any material, compound, mixture, or		
11	preparation which contains any quantity of the following		
12	substances, including its salts, isomers, esters, ethers, and		
13	salts of isomers, whenever the existence of these isomers,		
14	esters, ethers, and salts is possible within the specific		
15	chemical designation, that has a degree of danger or probable		
16	danger associated with a depressant effect on the central		
17	nervous system:		
18	(1) Alprazolam;		
19	(2) Barbital;		
20	(3) Bromazepam;		
21	(4) Butorphanol;		

2021-2263 HB1032 HD1 HMS0

1	(5)	Camazepam;
2	(6)	Carisoprodol;
3	(7)	Chloral betaine;
4	(8)	Chloral hydrate;
5	(9)	Chlordiazepoxide;
6	(10)	Clobazam;
7	(11)	Clonazepam;
8	(12)	Clorazepate;
9	(13)	Clotiazepam;
10	(14)	Cloxazolam;
11	(15)	Delorazepam;
12	(16)	Dichloralphenazone (Midrin);
13	(17)	Diazepam;
14	(18)	Estazolam;
15	(19)	Ethchlorvynol;
16	(20)	Ethinamate;
17	(21)	Ethyl loflazepate;
18	(22)	Fludiazepam;
19	(23)	Flunitrazepam;
20	(24)	Flurazepam;
21	(25)	Fospropofol (Lusedra);

2021-2263 HB1032 HD1 HMSO

1 (26) Halazepam;

# H.B. NO. <sup>1032</sup><sub>H.D. 1</sub>

		-	
2	(27)	Haloxazolam;	
3	(28)	Ketazolam;	
4	(29)	Loprazolam;	
5	(30)	Lorazepam;	
6	(31)	Lormetazepam;	
7	(32)	Mebutamate;	
8	(33)	Medazepam;	
9	(34)	Meprobamate;	
10	(35)	Methohexital;	
11	(36)	Methylphenobarbital	(mephorbarbital);
12	(37)	Midazolam;	
13	(38)	Nimetazepam;	
14	(39)	Nitrazepam;	
15	(40)	Nordiazepam;	
16	(41)	Oxazepam;	
17	(42)	Oxazolam;	
18	(43)	Paraldehyde;	
19	(44)	Petrichloral;	
20	(45)	Phenobarbital;	
21	(46)	Pinazepam;	

2021-2263 HB1032 HD1 HMSO

- 1 (47) Prazepam;
- 2 (48) Quazepam;
- 3 (49) Suvorexant;
- 4 (50) Temazepam;
- 5 (51) Tetrazepam;
- 6 (52) Triazolam;
- 7 (53) Zaleplon;
- 8 (54) Zolpidem; [and]
- 9 (55) Zopiclone (Lunesta) [-]; and
- 10 (56) Brexanolone."
- 11 2. By amending subsection (d) to read:

12 "(d) Stimulants. Unless listed in another schedule, any 13 material, compound, mixture, or preparation which contains any 14 quantity of the following substances having a stimulant effect 15 on the central nervous system, including its salts, isomers, and 16 salts of such isomers whenever the existence of such salts, 17 isomers, and salts of isomers is possible within the specific 18 chemical designation:

- 19 (1) Cathine ((+)-norpseudoephedrine);
- 20 (2) Diethylpropion;
- 21 (3) Fencamfamin;

2021-2263 HB1032 HD1 HMSO

# H.B. NO. <sup>1032</sup> H.D. 1

1	(4)	Fenproporex;	
2	(5)	Mazindol;	
3	(6)	Mefenorex;	
4	(7)	Modafinil;	
5	(8)	Phentermine;	
6	(9)	Pemoline (including organometallic complexes and	
7		chelates thereof);	
8	(10)	Pipradrol;	
9	(11)	Sibutramine;	
10	(12)	SPA (1-dimethylamino-1,2-diphenylethane, lefetamine);	
11		[and]	
12	(13)	Lorcaserin[-]; and	
13	(14)	<u>Solriamfetol.</u> "	
14	SECT	NON 4. Section 329-22, Hawaii Revised Statutes, is	
15	amended t	to read as follows:	
16	"§32	29-22 Schedule V. (a) The controlled substances	
17	listed in	n this section are included in schedule V.	
18	(b)	Narcotic drugs containing nonnarcotic active medicinal	
19	ingredie	nts. Any compound, mixture, or preparation containing	
20	limited quantities of any of the following narcotic drugs, which		
21	also contains one or more nonnarcotic active medicinal		

#### 2021-2263 HB1032 HD1 HMSO

## H.B. NO. <sup>1032</sup><sub>H.D. 1</sub>

1	ingredient	s in sufficient proportion to confer upon the
2	compound,	mixture, or preparation, valuable medicinal qualities
3	other than	those possessed by the narcotic drug alone:
4	(1)	Not more than 200 milligrams of codeine, or any of its
5		salts, per 100 milliliters or per 100 grams;
6	(2)	Not more than 100 milligrams of dihydrocodeine, or any
7		of its salts, per 100 milliliters or per 100 grams;
8	(3)	Not more than 100 milligrams of ethylmorphine, or any
9		of its salts, per 100 milliliters or per 100 grams;
10	(4)	Not more than 2.5 milligrams of diphenoxylate and not
11		less than 25 micrograms of atropine sulfate per dosage
12		unit;
13	(5)	Not more than 100 milligrams of opium per 100
14		milliliters or per 100 grams; and
15	(6)	Not more than 0.5 milligram of difenoxin and not less
16		than 25 micrograms of atropine sulfate per dosage
17		unit.
18	(c)	Stimulants. Unless specifically exempted or excluded
19	or unless	s listed in another schedule, any material, compound,
20	mixture,	or preparation that contains any quantity of the
21	following	g substances having a stimulant effect on the central

#### 2021-2263 HB1032 HD1 HMS0

1032 H.D. 1 H.B. NO.

nervous system, including its salts, isomers, and salts of 1 2 isomers. Depressants. Unless specifically exempted or excluded 3 (d) or unless listed in another schedule, any material, compound, 4 5 mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central 6 nervous system, including its salts, isomers, and salts of 7 8 isomers: 9 Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy~ (1) 10 propionamide], (Vimpat); (2) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic 11 12 acid]; and Brivaracetam ((2S)-2[(4R)-2-oxo-4-propylpyrrolidin-1-13 (3) 14 yl]butanamide) (Other names: BRV; UCB-34714; Briviact) 15 and its salts. 16 [-(e) Approved cannabidiol drugs. A drug product in 17 finished dosage formulation that has been approved by the United 18 States Food and Drug Administration that contains cannabidiol 19 (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-20 pentyl-1, 3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.]" 21

2021-2263 HB1032 HD1 HMS0

1032 H.D. 1 H.B. NO.

SECTION 5. Statutory material to be repealed is bracketed
and stricken. New statutory material is underscored.

**3** SECTION 6. This Act shall take effect upon its approval.

APPROVED this <sup>06</sup> day of <sup>JUL</sup> , 2021

Aarid y by

GOVERNOR OF THE STATE OF HAWAII

.



HB No. 1032, HD 1

#### THE HOUSE OF REPRESENTATIVES OF THE STATE OF HAWAII

Date: March 9, 2021 Honolulu, Hawaii

We hereby certify that the above-referenced Bill on this day passed Third Reading in the House of Representatives of the Thirty-First Legislature of the State of Hawaii, Regular Session of 2021.

Scott K. Saiki Speaker House of Representatives

This ille

Brian L. Takeshita Chief Clerk House of Representatives

#### THE SENATE OF THE STATE OF HAWAII

Date: **APR 13 2021** Honolulu, Hawaii

We hereby certify that the above-referenced Bill on this day passed Third Reading in the

Senate of the Thirty-First Legislature of the State of Hawaii, Regular Session of 2021.

MMAN. MA` onald D. Kouchi

President of the Senate

Carol T. Taniguchi Clerk of the Senate